This blog post is a web-formatted version of the Global Health Impact newsletter: Stronger Health Systems Stop TB and Save Lives (December 2015). (View or share the email version here.) We welcome your feedback and questions in the comments or email us. On social media, use hashtag #GlobalHealthImpact and tag @MSHHealthImpact. Subscribe
An estimated two billion people worldwide are infected with mycobacterium tuberculosis, more commonly known as tuberculosis, or TB. Despite major successes reducing global TB prevalence and mortality rates, TB is the single greatest infectious disease killer globally, surpassing HIV & AIDS. In 2014, 1.5 million people died from TB, including about 400,000 who also had HIV.
This post originally appeared on the Frontline Health Workers Coalition blog.
Ayelew Adinew was working as a pharmacist in a large public hospital in Addis Ababa, Ethiopia. He looked around and saw that the 100-year old pharmaceutical system was broken.
Although the global community has had significant success in reducing maternal and child deaths in the past two decades, they continue to die of preventable causes at an alarming rate. This is especially pronounced for the most vulnerable and hard-to-reach populations. Universal access to maternal, newborn, and child health (MNCH) commodities and services remains a major challenge, even among countries that are on track to achieve the Millennium Development Goals for reducing maternal and child mortality.
The highest rate of multi-drug resistant (M) and extensively drug-resistant (XDR) cases of tuberculosis (TB) is found in the World Health Organization (WHO) European Region. The Consolidated Action Plan to Prevent and Combat M/XDR-TB in the WHO European Region specifies that, by the end of 2013, all member states assure provision of an interrupted supply of quality first- and second-line medicines for treatment of all TB and M/XDR-TB patients.